{"id":63093,"date":"2026-04-14T15:33:30","date_gmt":"2026-04-14T07:33:30","guid":{"rendered":"https:\/\/flcube.com\/?p=63093"},"modified":"2026-04-14T15:33:30","modified_gmt":"2026-04-14T07:33:30","slug":"youcare-pharmaceutical-advances-dual-mrna-vaccine-pipeline-with-nmpa-approvals-for-rsv-and-herpes-zoster-candidates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63093","title":{"rendered":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates"},"content":{"rendered":"\n<p><strong>Youcare Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688658:SHA\">SHA: 688658<\/a>) announced separate <strong>clinical trial approvals<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for two proprietary <strong>mRNA vaccine candidates<\/strong>: <strong>YKYY025<\/strong> for the prevention of <strong>lower respiratory tract disease caused by respiratory syncytial virus (RSV)<\/strong> and <strong>YKYY026<\/strong> for the prevention of <strong>herpes zoster<\/strong>. Both candidates leverage Youcare&#8217;s proprietary <strong>LNP delivery system<\/strong> featuring cationic lipid <strong>YK-009<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>YKYY025 (RSV)<\/th><th>YKYY026 (Herpes Zoster)<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of RSV lower respiratory tract disease<\/td><td>Prevention of herpes zoster<\/td><\/tr><tr><td><strong>Antigen Target<\/strong><\/td><td>RSV F protein (pre-fusion conformation)<\/td><td>Varicella-zoster virus (VZV) gE protein<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I\/II clinical trials<\/td><td>Phase I\/II clinical trials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vaccine-technology-platform\">Vaccine Technology Platform<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ykyy025-rsv-mrna-vaccine\">YKYY025 \u2013 RSV mRNA Vaccine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antigen Design:<\/strong> Encodes pre-fusion conformation (pre-F) of RSV F protein<\/li>\n\n\n\n<li><strong>Sequence Innovation:<\/strong> Novel mRNA sequence with proprietary combination of mutation sites<\/li>\n\n\n\n<li><strong>Key Attributes:<\/strong> High expression efficiency, stable antigen structure, strong immunogenicity<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> Addresses significant unmet need in elderly and pediatric populations vulnerable to severe RSV infection<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ykyy026-herpes-zoster-mrna-vaccine\">YKYY026 \u2013 Herpes Zoster mRNA Vaccine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antigen Design:<\/strong> Encodes varicella-zoster virus (VZV) gE protein antigen<\/li>\n\n\n\n<li><strong>Sequence Innovation:<\/strong> Novel mRNA sequence with proprietary combination of mutation sites<\/li>\n\n\n\n<li><strong>Key Attributes:<\/strong> Novel structural configuration, strong immunogenicity profile<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Competes in growing herpes zoster vaccine market currently dominated by recombinant and live-attenuated approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-proprietary-delivery-system\">Proprietary Delivery System<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> Lipid nanoparticle (LNP) delivery system based on proprietary cationic lipid <strong>YK-009<\/strong><\/li>\n\n\n\n<li><strong>Performance Characteristics:<\/strong> High delivery efficiency and favorable safety profile<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Differentiated lipid chemistry potentially offering improved stability and reduced reactogenicity compared to standard LNP formulations<\/li>\n\n\n\n<li><strong>Platform Scalability:<\/strong> Same delivery system applicable across multiple mRNA vaccine candidates, enabling manufacturing efficiency<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China mRNA Leadership:<\/strong> Positions Youcare as a leading Chinese mRNA vaccine developer alongside global competitors<\/li>\n\n\n\n<li><strong>Dual Pipeline Approach:<\/strong> Simultaneous advancement of two high-value vaccine candidates demonstrates platform versatility<\/li>\n\n\n\n<li><strong>Market Opportunities:<\/strong><\/li>\n\n\n\n<li><strong>RSV Market:<\/strong> Global RSV vaccine market projected to reach $10 billion annually by 2030<\/li>\n\n\n\n<li><strong>Herpes Zoster Market:<\/strong> Current market valued at $3.5 billion with room for next-generation alternatives<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Potential for combination vaccine development and integration into existing immunization programs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<p>Youcare enters competitive mRNA vaccine space against established players including Moderna, Pfizer\/BioNTech, and CureVac, but benefits from first-mover advantage in China&#8217;s domestic mRNA vaccine market and potential preferential regulatory pathways for local developers.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations for YKYY025 and YKYY026. Actual results may differ due to risks inherent in vaccine development, including clinical trial outcomes, regulatory approvals, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688658_20260414_SXLC.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688658_20260414_SXLC.\"><\/object><a id=\"wp-block-file--media-3f1b331b-5ca3-47a7-b36d-6242753b6fba\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688658_20260414_SXLC.pdf\">688658_20260414_SXLC<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688658_20260414_SXLC.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3f1b331b-5ca3-47a7-b36d-6242753b6fba\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,63,1807,12,1808],"class_list":["post-63093","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-mrna","tag-sha-688658","tag-vaccine","tag-youcare-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China&#039;s National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare&#039;s proprietary LNP delivery system featuring cationic lipid YK-009.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates\" \/>\n<meta property=\"og:description\" content=\"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China&#039;s National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare&#039;s proprietary LNP delivery system featuring cationic lipid YK-009.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T07:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates\",\"datePublished\":\"2026-04-14T07:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093\"},\"wordCount\":452,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"mRNA\",\"SHA: 688658\",\"Vaccine\",\"Youcare Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63093#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63093\",\"name\":\"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T07:33:30+00:00\",\"description\":\"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China's National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare's proprietary LNP delivery system featuring cationic lipid YK-009.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63093\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates - Insight, China&#039;s Pharmaceutical Industry","description":"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China's National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare's proprietary LNP delivery system featuring cationic lipid YK-009.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63093","og_locale":"en_US","og_type":"article","og_title":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates","og_description":"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China's National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare's proprietary LNP delivery system featuring cationic lipid YK-009.","og_url":"https:\/\/flcube.com\/?p=63093","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T07:33:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates","datePublished":"2026-04-14T07:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63093"},"wordCount":452,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","mRNA","SHA: 688658","Vaccine","Youcare Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63093#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63093","url":"https:\/\/flcube.com\/?p=63093","name":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T07:33:30+00:00","description":"Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China's National Medical Products Administration (NMPA) for two proprietary mRNA vaccine candidates: YKYY025 for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) and YKYY026 for the prevention of herpes zoster. Both candidates leverage Youcare's proprietary LNP delivery system featuring cationic lipid YK-009.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63093"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63093\/revisions"}],"predecessor-version":[{"id":63099,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63093\/revisions\/63099"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}